The estimated Net Worth of Ryan D Maynard is at least 578 千$ dollars as of 8 February 2024. Mr. Maynard owns over 5,488 units of Iovance Biotherapeutics Inc stock worth over 74,912$ and over the last 18 years he sold IOVA stock worth over 2,909$. In addition, he makes 500,363$ as Independent Director at Iovance Biotherapeutics Inc.
Ryan has made over 6 trades of the Iovance Biotherapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,488 units of IOVA stock worth 2,909$ on 8 February 2024.
The largest trade he's ever made was exercising 100,000 units of Iovance Biotherapeutics Inc stock on 3 November 2017 worth over 214,000$. On average, Ryan trades about 5,748 units every 127 days since 2006. As of 8 February 2024 he still owns at least 8,012 units of Iovance Biotherapeutics Inc stock.
You can see the complete history of Mr. Maynard stock trades at the bottom of the page.
Ryan D. Maynard serves as Independent Director of the Company. Mr. Maynard joined our Board of Directors in February 2015. Mr. Maynard was appointed as the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company in February of 2018. Until December 2017, he was the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel’s Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999 he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as a Senior Finance Manager. He previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce - Accounting from Santa Clara University.
As the Independent Director of Iovance Biotherapeutics Inc, the total compensation of Ryan Maynard at Iovance Biotherapeutics Inc is 500,363$. There are 9 executives at Iovance Biotherapeutics Inc getting paid more, with Maria Fardis having the highest compensation of 4,107,960$.
Ryan Maynard is 50, he's been the Independent Director of Iovance Biotherapeutics Inc since 2015. There are 10 older and 5 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.
Ryan's mailing address filed with the SEC is C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS, CA, 94070.
Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over 0$ worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth 159,655,586$ . The most active insiders traders include Wayne P. Rothbaum、Merrill A Mcpeak、Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of 3,815,146$. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth 535,680$.
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include: